The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation, prompting investors to reassess their portfolios.
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington, managing partner at Requisite Capital Management, said if AbbVie Inc. (NYSE:ABBV) can break above $197, it marches towards its all-time high level.
According to recent news, IGI Therapeutics SA, a wholly owned subsidiary of Ichnos Glenmark Innovation Inc., and AbbVie announced on Thursday an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for the treatment of oncology and autoimmune diseases.
Kevin Simpson, founder and CEO
The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation, prompting investors to reassess their portfolios.
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington, managing partner at Requisite Capital Management, said if AbbVie Inc. (NYSE:ABBV) can break above $197, it marches towards its all-time high level.
According to recent news, IGI Therapeutics SA, a wholly owned subsidiary of Ichnos Glenmark Innovation Inc., and AbbVie announced on Thursday an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for the treatment of oncology and autoimmune diseases.
Kevin Simpson, founder and CEO
The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation, prompting investors to reassess their portfolios.
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington, managing partner at Requisite Capital Management, said if AbbVie Inc. (NYSE:ABBV) can break above $197, it marches towards its all-time high level.
According to recent news, IGI Therapeutics SA, a wholly owned subsidiary of Ichnos Glenmark Innovation Inc., and AbbVie announced on Thursday an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for the treatment of oncology and autoimmune diseases.
Kevin Simpson, founder and CEO Read MoreABBV, BA, JOBY, Long Ideas, News, ORCL, Markets, Media, Trading Ideas, ORCL, US68389X1054, BA, US0970231058, ABBV, JOBY, Long Ideas, News, Markets, Media, Trading Ideas, Benzinga Markets
